Ideal Power: Revenue Ramp And Stellantis Phase 3 Around The CornerBy mariocazombo76@gmail.com / February 28, 2025
NewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of Obicetrapib March 1, 2025 / NAMS, Tejo Strategy Investing / By mariocazombo76@gmail.com
aTyr Pharma: Good Safety Data In Pulmonary Sarcoidosis, Institutions Are Accumulating March 14, 2025 / ATYR, Tejo Strategy Investing / By mariocazombo76@gmail.com
By
/ February 28, 2025 By
/ February 28, 2025 By
/ February 28, 2025 By
/ February 28, 2025 By
/ February 28, 2025 By
/ February 28, 2025